ATM and neoplasm: The NCCN guidelines (version 2.2021, July 2022) propose consideration of tumour testing for HR repair mutations (BRCA1/2, ATM, CHEK2, PALB2, FANCA, RAD51D, and CDK12), as well as microsatellite instability or MMR status (MLH1, MSH2, MSH6, and PMS2) in patients with regional, high-risk localised or metastatic prostate cancer [102].